Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10 mai 2024 14h56 HE | Optinose, Inc.
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Logo 400x400.jpg
CytoSorbents Reports First Quarter 2024 Results
09 mai 2024 16h17 HE | CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
08 mai 2024 09h15 HE | Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Arbutus Biopharma Logo
Arbutus to Participate in Two Upcoming Investor Conferences
07 mai 2024 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
BioNTech veröffentli
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung
06 mai 2024 06h45 HE | BioNTech SE
BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen: weitere Phase-3-Studie mit der Behandlung der...
BioNTech Announces F
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
06 mai 2024 06h45 HE | BioNTech SE
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03 mai 2024 07h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
02 mai 2024 07h30 HE | Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
MYR Group logo
MYR Group Inc. Announces First-Quarter 2024 Results
01 mai 2024 16h13 HE | MYR Group, Inc.
THORNTON, Colo., May 01, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial...
01 mai 2024 16h05 HE | FAT Brands Inc.
Conference call and webcast today at 5:00 p.m. ET LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”) today...